Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Ocugen, Inc. is a U.S.-based biotechnology company dedicated to the discovery, development, and commercialization of innovative gene and cell therapies, biologics, and vaccines. Their primary focus is on addressing unmet medical needs in rare and underserved eye diseases, as well as developing vaccines for infectious diseases. Ocugen aims to leverage its modifier gene therapy platform and other proprietary technologies to deliver transformative treatments to patients worldwide.
Ocugen's headquarters in Malvern serves as the central hub for its corporate administration, research and development leadership, clinical operations management, and strategic business development activities.
Located within the Great Valley corporate center, a well-known hub for life sciences and technology companies, providing a modern and collaborative environment. Proximity to Philadelphia's rich biotech ecosystem.
Ocugen likely fosters a science-driven, innovative, and patient-focused work culture. Emphasis is placed on collaboration, scientific rigor, and a commitment to advancing medical breakthroughs for diseases with high unmet needs.
The Malvern headquarters is critical for coordinating Ocugen's global clinical trials, managing regulatory affairs with bodies like the FDA, and steering the company's overall strategic direction and partnerships.
Ocugen's global presence is primarily characterized by its international clinical trial operations conducted across multiple countries, engagement with global regulatory authorities for its product candidates, and strategic collaborations for development and potential commercialization. While its physical corporate presence is centered in the U.S., its operational and strategic reach is international, particularly in advancing its gene therapy and vaccine programs.
263 Great Valley Parkway
Malvern
PA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Ocugen' leadership includes:
Ocugen has been backed by several prominent investors over the years, including:
Over the past 12 months, Ocugen has strengthened its leadership team with key appointments, particularly in medical and clinical development roles, including a new Chief Medical Officer and a Senior Vice President of Clinical Development. There was also a transition in the Chief Medical Officer position.
Discover the tools Ocugen uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Ocugen, Inc. typically uses a standard corporate email format. The most commonly observed pattern is [first name].[last name]@ocugen.com. Other variations might exist but this is a strong primary pattern.
[first].[last]@ocugen.com
Format
jane.doe@ocugen.com
Example
75%
Success rate
Ocugen, Inc. (GlobeNewswire) • May 9, 2024
Ocugen announced its financial results for Q1 2024, highlighting progress in its pipeline including its OCU400 gene therapy for retinitis pigmentosa and OCU200 for diabetic macular edema. The company also provided updates on its regenerative cell therapy and vaccine programs....more
Ocugen, Inc. (GlobeNewswire) • April 25, 2024
Ocugen reported positive top-line data from its Phase 1 clinical trial of OCU200, a novel biologic product candidate for treating Diabetic Macular Edema (DME). The study met its primary safety and tolerability endpoints....more
Ocugen, Inc. (GlobeNewswire) • March 26, 2024
Ocugen announced that the U.S. FDA granted Orphan Drug Designation (ODD) for OCU410ST (AAV-hRORA), its modifier gene therapy candidate for the treatment of Stargardt disease, a rare genetic eye disorder....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Ocugen, are just a search away.